



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

## ***Table of Contents***

Copyright VENTURE PLANNING GROUP  
This material is confidential for use by our clients only  
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients ***www.VPGcorp.com***

VPG Market Research Reports ***www.VPGMarketResearch.com***

Partner Reports ***www.LeadingMarketResearch.com***

**VENTURE PLANNING GROUP** 1271 Avenue of the Americas, Suite 4300 New York, NY 10020  
Phone + 1 212 564 2838 ***reports@vpgcorp.com***

## **Table of Contents**

### **I. Introduction**

### **II. Worldwide Market Overview**

1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth

### **III. Major Product Development Opportunities**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

### **IV. Design Criteria for Decentralized Testing Products**

### **V. Alternative Market Penetration Strategies**

- A. Internal Development
  - B. Collaborative Arrangements
  - C. University Contracts
  - D. Distribution Strategies
- 
1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

### **VI. Potential Market Entry Barriers and Risks**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## Table of Contents

### **VII. Worldwide Market and Technology Overview**

#### A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

#### B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes

## Table of Contents

- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
  - ADA
  - B-Protein
  - PNP
  - 5'-Nucleotidase
- 27. Oncogenes
  - Abl/abl-bcr
  - AIB1
  - BCL-2
  - BRCA1
  - CD44
  - C-fos
  - C-myb
  - C-myc
  - CYP-17
  - Erb-B
  - HPC1
  - N-myc
  - P40
  - P51
  - P53
  - PIK3CA
  - PTI-1
  - Ras
  - Reg
  - Sis
  - Src
- 28. Polypeptide Growth Factors
  - Basic Fibroblast Growth Factor
  - Beta-TGF
  - Cachectin (TNT)
  - Calmodulin
  - ECFR
  - Nerve Growth Factor (NGF)
  - Epidermal Growth Factor (EGF)
  - Ornithine Decarboxylase
  - Transferrin
  - Transforming Growth Factor-Alpha

## Table of Contents

- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines
  - Alpha-Interferon
  - B Cell Growth Factors
  - B Cell Growth Factor (BCGF)
  - Gamma-Interferon
  - Interleukin-1 (IL-1)
  - Macrophage Activating Factor
- 32. Immunohistochemical Stains
- 33. Emerging Tumor Markers
  - N-Acetylglucosamine
  - Actin
  - Alpha-Actin
  - Antineuronal Antibodies
  - 7B2
  - B72.3
  - Bax
  - BCD-F9
  - BLCA-4
  - Blood Group Antigens A,B,H
  - CA 50
  - CA 72-4/TAG-72
  - CA 195
  - CA-242
  - CA-549
  - CAM 26
  - CAR-3
  - Cathepsin-D
  - Chromogranin A and B
  - Cluster 1 Antigen
  - Cluster-5/5A Antigen
  - CTA
  - CU18
  - DR-70
  - DU-PAN-2
  - Endometrial Bleeding Associated Factor
  - Endostatin
  - Epithelial Membrane Antigen
  - Feulgen Hydrolysis
  - Fibronectin

## Table of Contents

- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

## Table of Contents

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen

### C. Instrumentation Review And Market Needs

### D. Current and Emerging Technologies

#### 1. Molecular Diagnostics

- a. Technology Overview
- b. Amplification Methods
- c. Sequencing
- d. Microarrays/Biochips

#### 2. Monoclonal and Polyclonal Antibodies

#### 3. Immunoassays

- a. Technological Principle
- b. Radioimmunoassay (RIA)
- c. Enzyme Immunoassays (EIA)
  - Overview
  - ELISA
  - Immunofiltration
  - Particle-Membrane Capture Immunoassay
  - Enzyme Amplification

## Table of Contents

- d. Fluorescent Immunoassays
  - e. Luminescence
    - Chemiluminescence
    - Bioluminescence
  - f. Latex Agglutination
  - g. Immunoprecipitation
  - h. Affinity Chromatography
  - e. Liposome Flow-Injection Immunoassay
  - 4. Chromosome Analysis
    - a. Chronic Myelogenous Leukemia (CML)
    - b. Acute Myeloid Leukemia (AML)
    - c. Acute Lymphoblastic Leukemia (ALL)
    - d. Malignant Lymphomas Lymphoid Malignancies
    - e. Chronic Lymphocytic Leukemia (CLL)
    - f. Solid Cancers
    - g. Chromosomal Translocation and Oncogenes
  - 5. Artificial Intelligence
  - 6. Flow Cytometry
  - 7. Two Dimensional Gel Electrophoresis (2-DGE)
  - 8. Biosensors
  - 9. Competing/Complementing Technologies
    - a. CT
    - b. MRI
    - c. NMR
    - d. PET
    - e. Photonics Spectroscopy
- E. Personal Testing

### **VIII. France**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares



## Table of Contents

### **IX. Germany**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

### **X. Italy**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

### **XI. Japan**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

### **XII. Spain**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

### **XIII. U.K.**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

## Table of Contents

### **XIV. U.S.A.**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales  
And Market Shares

### **XV. Competitive Profiles**

- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako

### **XVI. Appendix:** Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications